Elevance Health tops Q2 2026 estimates as CEO buys 680 shares

Adjusted earnings per share of $7.45 and revenue of $49.83 billion both beat forecasts, while Gail Boudreaux’s purchase at $366.41 signaled confidence after the results.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.